Navigation Links
12-Month Study Reports Efficacy Rates for AMS' Elevate Apical and Posterior Prolapse Repair System
Date:9/21/2010

MINNEAPOLIS, Sept. 21 /PRNewswire/ -- American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the results of a 12-month single-arm, prospective multi-center study of the Elevate® Apical and Posterior Prolapse Repair System.  The pelvic organ prolapse quantification exam (POP-Q), used to quantify, describe, and stage pelvic support, was implemented in the study and concluded efficacy rates of Stage 1 or less to be 89.2% for Apical and 91.7% for Posterior.

The results presented at IUGA/ICS meeting also show that 98.4% of patients treated with the Elevate system would recommend the procedure to a friend.  The study was conducted at sixteen centers in the U.S., Canada, Belgium and UK.

Elevate is a minimally invasive, comprehensive solution to treat apical and posterior defects.  The total transvaginal approach is designed to minimize tissue trauma.  Elevate offers safe, simple and precise apical mesh placement in the sacrospinous ligament through a single vaginal incision.

"Our findings indicate that Elevate offers a prolapse repair technique that is safe with low morbidity and minimal postoperative pain," said Dr. James Lukban, principal investigator of the study.  "Our study concluded that Elevate Apical and Posterior is effective in terms of anatomic correction and improvement in day-to-day symptoms at one year, with ongoing analysis through 24 months."

"Over 34 million women worldwide are affected by vaginal prolapse.  This study provides reliable data that can help patients and their doctors make decisions about treatment options to improve quality of life and restore pelvic anatomy," stated John Nealon, senior vice president and general manager of Women's Health at AMS.

The Elevate Apical and Post
'/>"/>

SOURCE American Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
2. 12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
3. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
4. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
5. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
6. Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
7. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
8. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
9. Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Array BioPharma Inc. (NASDAQ: ARRY ) today ... year of its fiscal year ended June 30, ... Array, noted, "Binimetinib and encorafenib, two innovative oncology ... regulatory submissions in 2016. Additional data shared over ... cancer further validate the value of these programs ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... been appointed to the Board of Directors, effective July ... II Director until the 2018 annual meeting or until ... McDougal has served in an executive capacity in the ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
... Pfizer (NYSE: PFE ) today ... Inc., a privately held drug discovery and clinical development ... a wholly owned subsidiary of Pfizer Inc.   ... Pfizer Inc: Working together for a healthier ...
... Baxano, Inc. ( www.baxano.com ) today announced that two of ... Spine Care at the 2010 Spine Technology Awards. The iO-Flex™ ... in the Best New Technology in Lumbar Care. ... Technology Awards Gala in Orlando, FL. Baxano, Inc. was awarded ...
Cached Medicine Technology:Baxano, Inc. Awarded Prestigious 2010 Spine Technology Awards 2
(Date:8/3/2015)... ... August 03, 2015 , ... As reported in ... Lifetime reality series, “Atlanta Plastic” is getting attention for moving outside traditional ethnic ... its predominantly African-American cast of doctors and patients. Beverly Hills based plastic surgeon ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to ... related claims in which a claimant alleged to have suffered an arterial blood clot ... birth control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to Monitor ... of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to ... , A cooperative agreement awarded by the U.S. Agency for International Development ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... notes that while an overwhelming number of Hispanics believe people can positively ... overwhelming 70 percent of participants queried said making diet changes was important. Far ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Dental practice ... help patients in need. Most people know that general health emergencies, such as broken ... fewer amount of people know where to turn to during a dental emergency. This ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3
... Meeting on Lessons from 2004 Tsunami, WASHINGTON, ... psychosocial support responders are meeting to,discuss how disasters ... operations in response to the 2004 tsunami. The ... the American Red Cross. The,American Red Cross oversees ...
... 360m Collaboration with Harvard Medical International Provides ... and Vital Global Health Information, BALTIMORE, Jan. 29 ... the reach of their groundbreaking MEDEX,360m partnership with the ... business and leisure travelers., Like the original MEDEX ...
... 29 /PRNewswire/ - There is new hope for ... called DizzyFIX,patients with vertigo can now treat themselves. ... this visual device helps treat the most common,type ... DizzyFIX has received a number of medical ...
... but unless we harness the powers of our microbial co-habitants ... according to an article in the February 2008 issue of ... organisms that we are, it is easy to view this ... Reay from the University of Edinburgh. In truth of course, ...
... enterprise security, reduces risk and ... ... a global,provider of integrated security, risk and audit management solutions, ... National,Health Service (NHS) has selected its flagship SecureVue(R) platform to,proactively ...
... of Respondents Feel Their Overall Health Affects Their,Recovery ... Mental Health,America of San Diego today released ... overall healthcare in mental health settings from the,perspective ... that although both groups are aware of actions ...
Cached Medicine News:Health News:Global Experts Convene to Discuss Emotional Trauma Caused by Disasters 2Health News:MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers 2Health News:All Star Sales Introduces DizzyFIX a New Treatment for Vertigo and Dizziness 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 3Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 2Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 3Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: